Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

Bayer cuts loose diabetes care division for 1.02bn euros

June 10, 2015
Life sciences
Bayer is shedding its diabetes care division via a deal with long-term partner Panasonic Healthcare Holdings worth 1.02 billion euros.
 
The sale includes blood glucose monitoring systems, including the popular Contour portfolio of testers and strips, as well as lancing devices for patients with diabetes, which helped the unit bring in sales of 909 million euros last year.
 
The move seems a good fit for Panasonic. “For more than 20 years, our companies have shared complementary goals. We anticipate that this partnership will take our two great businesses to new heights,” said Kenji Yamane, President of Panasonic Healthcare Holdings, which is owned by investment group KKR (80%) and Panasonic Corp (20%). 
 
For Bayer, the transaction comes under its current strategy of honing its focus on life-sciences, as per which it also plans to de-merge and float on the stock market its MaterialScience unit by mid-2016.
 
The deal with Panasonic, which remains subject to customary conditions, including relevant antitrust clearance, is expected to close in the first quarter of next year.
 
By Selina McKee
 

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Read more
September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Read more
September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

Read more
More news

How can we help you?

We're easy to reach